ARCHIVES

Phase III Custirsen/Docetaxel/Prednisone Trial Fails Primary Endpoint of Overall Survival

This article is from The Cancer Letter archive.

Vol. 37 No. 4 | April 25, 2014

Download PDF Visit The Full Archive

Related Articles

New Jersey Commission Calls For Major Hike In Cancer Spending

September 25, 1987

NCI-Approved CTEP Trials For The Month of July

July 27, 2012

Medical Advances Not Driven Entirely By Science, Author Physician Barron Lerner Tells Journalists

March 22, 2002

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

Mayo Clinic Study Finds Samarium May Expand Options For Osteosarcoma

February 22, 2002

Cancer Mortality By County For 1950-69 Now Available From GPO; Price-$9

April 26, 1974